TP53 and acute myeloid leukemia: Indeed, the patient cohort of MDS-R mutations in this study included a few patients with ICC and ELN-2022 defined AML with mutated TP53. In the analysis focusing only on patients without TP53 mutations, we found that the poor prognostic impact of MDS-R mutations remained: the patients with MDS-R mutations had poorer OS (P < 0.001 for total cohort; P = 0.006 for elderly patients; P = 0.038 for younger patients) compared with those without MDS-R mutations.